key: cord-0876368-utbin0jj authors: Barrett, Ravina; Barrett, Robert; Dhar, Kalyan; Birch, Brian title: Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020) date: 2021-08-19 journal: BJUI Compass DOI: 10.1002/bco2.101 sha: f56c26c0d4fbc501de88194d6ff4003251ab67de doc_id: 876368 cord_uid: utbin0jj OBJECTIVE: To examine the effect of the COVID‐19 pandemic on gonadorelin analogue prescription for community patients in England. MATERIALS AND METHODS: We included data from all primary‐care patients who had relevant prescriptions dispensed in the community in England. Descriptive statistics and interrupted time series analysis over 22 months (15 months before and 7 months after lockdown) was evaluated. RESULTS: A total of 22 months’ worth of data were analyzed (or 1 041 638 total items, monthly average 47 347 items). Goserelin; leuprorelin, and triptorelin are the medicines most used by total quantity in the study period. Simple descriptive statistics show that mean values have declined during the pandemic. The Interrupted Time Series (ARIMA Modeling) shows declining trends. After the pandemic's onset, we observe a statistically significant downward trend for goserelin (P = .017) and leuprorelin (P = .014). As these are the major constituents of the model, we interpret this overall data as showing a significant downward category trend. Aside from linearity, a significant step change was noted for leuprorelin (P = .029) showing an increase in prescription items with a similar effect that is close to being statistically significant for goserelin (P = .051). The actual cost of medicines shows minimal variation suggesting that prices of individual medicines have remained stable. The regional data showed variation but this was not statistically significant. In all cases, the Oct‐20 figures are lower “year on year.” This novel work reports the impact of a global pandemic on prescription volumes of prostate cancer (PCa) medicines. CONCLUSIONS: A worrying decrease in prescription medicines raises concerns for the care of PCa patients. We encourage diagnosed patients to discuss their planned care with their doctor. The PCa treatment is intended to relieve symptoms, achieve disease remission and improve overall quality of life. From a public health, primary care perspective, it is important that these (potentially elderly) patients continue to get their medicines at timely regular intervals to ensure disease progression is delayed as long as feasibly possible. Due to the variable recovery of the HPA, natural testosterone levels recover slowly and so in patients exhibiting a good response to treatment discontinuation of therapy (intermittent ADT) is feasible. However, at some time patients usually stop responding to ADT and experience rising PSA levels despite castrate levels of serum testosterone (castrate resistant PCa or castrateresistant prostate cancer). 20 However, due to the variable recovery of the HPA, natural testosterone levels sometimes never recover and discontinuation of therapy (intermittent ADT) is feasible. For younger patients, if timely administration is missed, rising testosterone levels may cause further disease progression. 21, 22 Generally, cancer sufferers are also at higher risk of contracting infections (eg LUTS, , as a consequence of the cancer itself or the medication they take to treat it. Triptorelin (Decapeptyl® and Gonapeptyl®), leuprorelin (Prostap®), and goserelin (Zoladex®) are GnRH analogues licensed for use monthly, 3-monthly, or 6-monthly in the form of prefilled syringes and vials. National Institute for Health and Care Excellence (NICE) guidelines 23 recommend that men with PCa should be followed up in primary care according to locally agreed protocols. For men with advanced disease guidelines suggest the use of GnRH analogues if PSA levels are above locally agreed thresholds or if there is symptomatic progression. In normal clinical practice, we expect to see patients attending the GP surgery at monthly, 3-monthly or 6-monthly intervals for "top up" injections to control disease as evidenced by a low PSA. As a result, there should be minimal variation in prescription volumes. This study hypothesizes that the COVID-19 pandemic would not affect community prescription issuance of GnRH analogues and that prescription volumes would be relatively stable during the first wave of the pandemic in England. The "English Prescribing Dataset" (EPD) 20 contains public sector information licensed under the Open Government Licence V2.0, which provides anonymized prescription data in England. 24 The EPD contains detailed information on community-issued prescriptions (not K E Y W O R D S COVID-19, follow-up, gonadotropin-releasing hormone, hormonal therapy, male, prostate cancer hospital) issued in England but which were dispensed across the UK (England, Wales, Scotland, Guernsey, Alderney, Jersey, and the Isle of Man). It contains detailed prescribing information at practice level, which are aggregated by British National Formulary (BNF) code (eg, 0803042P0AAACAC for "Triptorelin 11.25 mg inj vials") to maintain patient confidentiality. Therefore, each row of data is aggregated at practice level and does not represent individual patients or prescriptions. The data include total quantity of unit-doses (eg, pre-filled syringes, vials), and "actual cost" for reimbursement. The data exclude prescriptions issued outside England (Wales, Scotland, Guernsey, Alderney, Jersey, and the Isle of Man-this difference is solely to do with where prescriptions were issued as opposed to where dispensed); items not dispensed, disallowed, and those returned for further clarification; prescriptions prescribed and dispensed in prisons, hospitals, and private prescriptions; items prescribed but not presented for dispensing or not submitted to NHS prescription services by the dispenser. This dataset includes small operational irregularities (eg, 17 rows in Jan 2019 of "unidentified practice data," 470 rows of "NULL" chemical substance codes where accurate BNF codes were given to permit extraction of the missing data). The study population represents English residents who were issued a prescription and had it dispensed. Monthly data from January 2019 to October 2020 were examined for all potential PCa medicines and included (Goserelin Acetate Approximately 387 288 884 rows of data (528.8 gigabytes of data) were extracted using Structured Query Language (SQL). After excluding unnecessary rows, the data were filtered down to 12 092 relevant rows of data. Twenty-two comma-separated values (CSV) files were imported into a Microsoft SQL® server table labeled EPD. As each one was imported, it was validated and assigned an exact data type (eg, "Total quantity" is a "floating" data point, "regional office name" is a textfield) to each field of data. The data were cleaned by the removal of spaces, blanks, and checked for incorrect data formatting (eg, that text characters were not in a numeric field or vice versa). Microsoft Visual Studio® was used to create and edit SQL Server Integration Services® (SSIS) packages that imported, validated, and consolidated the data within an automated import routine, (see Supplemental Methods [Data Cleaning]) for details. Data were aggregated by month, chemical substance, regional office name, and BNF code, to allow for human analysis. The CSV data allow for comparison across months. Detailed population analyses were not conducted and were assumed to be constant. The target population cohorts consisted of patients prescribed and dispensed these medicines, but their exact diagnosis remains undocumented and therefore unknown. Lockdown commenced on March 23, 2020 with subsequent local and national lockdowns. Interrupted time series (ITS) analysis was used to fit time trends. 25 A commonly used time series modeling framework (autoregressive integrated moving average or ARIMA) was employed to analyze the monthly total-quantity of prescription data from the EPD. ARIMA is a flexible modeling construct, allowing lagged correlations and seasonal differences to be modeled, but we initially used only a simple model with no allowance for serial correlation nor seasonality, mainly due to the lack of data points after the interrupt time point. We had Ethical approval was not required for this database study and no patient identifiable data were accessed. There was no public and patient involvement. A total of 22 months' worth of data were analyzed (or 1 041 638 total items, monthly average 47 347 items), using March 2020 as the cut-point for the first lock-down in England, making it nationally representative. Goserelin acetate; Leuprorelin acetate; Triptorelin (Acetate) and Triptorelin embonate are the medicines most used by total quantity in the study period (see Figure S1 and Supplemental Results [ Table S1 ]). We present price-data in Supplemental Results (Table S2 ). Regional analysis is presented in Supplemental Results ( Figure S1 , Table S3 ). See also detailed individual formulations analysis on Total Quantity and Actual Costs in Supplemental Results (Table S4, Table S5 ). Simple descriptive statistics of the 15 months before the pandemic and the 7 months after its onset are presented in Table 1 , which shows that mean values have declined during the pandemic except for Triptorelin embonate which is proportionately, a smaller constituent. Given its relative lack of use, its exclusion was considered, but is presented here for completeness. Percentage changes are also noted in the final column of Table 1 , for potential population of 47 000 patients. Since prescription data are not random, a 1-month autocorrelation better reflects routine clinical practice. The model allows for correlation with the previous month's prescription volumes (see Table 2 and Figure 1 ). Table 2 suggests that steadily growing monthly parameter estimates of the injectables before the pandemic go into accelerated reversal after March 2020, but are accompanied with a positive step change. In supplemental sensitivity analysis, we find significant percentage changes for each medicine within our model using a natural logarithm transformation. 27, 28 We estimate the percentage changes as an autoregressive function at 1 month lag, however, this should be interpreted with caution. 29 Before the pandemic, Triptorelin acetate (P = .021) was showing evidence of increasing prescription volumes, which is captured in the significant linear trend for prescription statistics before March 2020. After the pandemic's onset, we observe a statistically significant downward trend for goserelin (P = .017) and leuprorelin (P = .014) accompanied with much lower confidence intervals. As these are major constituents of the model, we interpret this overall data as showing a significant downward category trend. Aside from linearity, we also examined whether there was a step change. A significant step change was noted for Leuprorelin (P = .029) showing a jump in prescription items with a further jump that is close to being statistically significant for goserelin (P = .051). Collectively, this tells us that significant changes in prescription statistics were noted for 7 months after the pandemic's onset as compared to the 15 months period before. Table S4, Table S5) shows that there is a growing preference for the 6-month formulation (37% increase for Decapeptyl SR 22.5 mg inj vials and 20% increase for Triptorelin embonate 22.5 mg inj vials) as the pandemic progresses, with a related decreased preference for the 1-month products. This indicates switching within the drug category in preference for agents with longer posology. The 6-month formulations are normally reserved for female patients, but our analysis suggests that practice is adapting pragmatically. No seasonal effects are expected because follow-up appointments should be anticipated and prescheduled. In light of this, unexpectedly low prescription volumes were identified in August 2020 (goserelin 17 661, leuprorelin 15 987, and triptorelin acetate 6375). The actual cost of medicines shows minimal variation in "Results Supplemental Table S3 " that tracks the total quantity changes described above. This suggests that prices of individual medicines have remained stable over the study period. The EDP presents data by "regional office name." Nomenclature for regional territories except London was modified in April 2020, making it difficult to make direct comparisons across regions before and after this period. However sufficient clarity is provided to permit the re-aggregation of the data (April-July 20) to allow for direct com- Supplemental Figure S1 and Table S4 ." This shows variation was substantial in some regions, though not statistically significant, with some unlabeled records. In all cases, the October 2020 statistics TA B L E 1 Descriptive statistics for the monthly total quantities of prescribed medicines items-standard deviation (STD), 95% confidence intervals (CI) Hence, the assumption that the cohort was "constant" remains valid. TA B L E 2 ARIMA (1,0,0)(0,0,0) Model Parameters-Estimated change in prescription volumes at March 2020, Confidence intervals (CI); T-statistic (T, Stat); standard error (SE) We know, in gynecology, that GnRH analogues are used in endometriosis and in vitro fertilization (IVF). For endometriosis, the duration of use is usually 6 months within secondary care with some GP issued repeat prescriptions. All IVF management is either in tertiary care or private settings. Therefore, the changes in the pattern of prescription for GnRH analogues observed in this study pertains predominantly to PCa patients, which is a cause for concern. The female patient population is a small proportion and has been stable historically. So changes in this patient group are unlikely to explain the variations we observe. There is no evidence to suggest that prescriptions in women who be handled any differently to those in men. Prescription volumes have declined and even if this is not linked to significant morbidity now, it is a proxy for medicines-supply or patient-access and an important avenue for further enquiry. For the first time, we present data on prescription and regional variations during this pandemic for medicines licensed for the treatment of PCa. This provides an early signal for potentially deteriorating medium to longer term health in this group of patients. The data provide immediate decision-making capacity which can be implemented to mitigate clinical risks for these patient groups. Anecdotally, this could be for a variety of reasons including higher mortality within this patient group from COVID-19, patient reluctance to leave home especially if they are shielding, and if they are on "patient triggered follow up" regimes with an emphasis put on the patent to contact the GP surgery for the next injection rather than vice versa. GP factors may also play a role and although surgeries normally have processes in place to enable patient recall and offer treatment at home where appropriate. However, in a pandemic, these processes may be less robust and patient perception has been that contacting their GP surgeries is very difficult and even that they are "closed." As researchers, we encourage improvement in the documentation and data-structure of the dataset used. The need for error-free data, its completeness, and the importance of documenting indications for medications is vital in facilitating better research that allows granular targeting of patient groups, as we have done here. Data collection, duration, and completeness requires that the data be representative of practice across the UK and should incorporate datasets from Scotland, Wales, and Northern Ireland income parable, or interoperable data presentations for completeness. This would allow early detection of regional variations to care. There has also been significant disruption to the supply chain before and during COVID, coupled with pharmacy reimbursementrenegotiations and manufacturing issues affecting medicine supply across Europe, but which do not affect these medicines. 35 Another consideration is the "prescribing" vs. "dispensing" practice: we known that varied prescribing practice occurred, deviating from routine issuance of a "28-day" prescription (in some cases, people were issued up to 6 months' worth of medication While we find statistically significant data, this may not be clinically relevant immediately for all affected patients. However, these data trends may continue in the second and third wave of lockdowns in the UK and can become entrenched, which would mean that a "clinical urgency" may appear unexpectedly. This has implications for clinical practice-we encourage prescribers to maintain clear documentation of offered follow-up and alternative care provided to guard against negligence cases and to actively think about patient-lists. Gynecological and urological specialists have an important leadership role to guide policy and the direction of patient care within a multidisciplinary team in concert primary care which is rapidly reconfiguring. The evidence we present may support them in considering alternative models of care for their patients, including exploring innovative practices. Bilateral orchidectomy remains an option for locally advanced and metastatic cancers, but is unlikely to apply to the majority population. It is likely that delayed diagnosis and deprioritization of patient lists may mean that patient numbers (and therefore prescriptions) will substantially rise in the future. Population demographics also support increased GnRHa use in an aging cohort and workload and workforce preparedness should be considered. There are several strengths to this study. For the first time, we report the impact on prescription volumes of medicines licensed for PCa in England during a global pandemic. Strengths of this study include being evidence-based using real world data. One of the strengths of ITS studies is that they are generally unaffected by typical confounding variables which remain fairly constant, such as population age distribution or socioeconomic status, as these only change relatively slowly over time. Nevertheless, ITS can be affected by time-varying confounders (eg, excess mortality) that change more rapidly. 38 We acknowledge that the indications for the medicines analyzed are unknown and no clear correlation with adverse outcomes appears in the literature. Tackling non-metastatic castrationresistant prostate cancer: special considerations in treatment Diagnostic and therapeutic strategies for prostate cancer Screening for prostate cancer Cancer registration statistics, England-Office for National Statistics United Nations Statistics Division. SDG Indicators-Global indicator framework for the Sustainable Development Goals and targets of the 2030 Agenda for Sustainable Development United Nations. A data revolution in motion. Epub ahead of print 20 Innovative diagnostic methods for early prostate cancer detection through urine analysis: a review Prostate cancer: diagnosis and management. NICE guideline 131 Zoladex 3.6mg Implant-Summary of Product Characteristics (SmPC)-(emc) Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy GnRH analogues for the treatment of fibroids An overview of treatments for endometriosis GnRH and GnRH receptors in the pathophysiology of the human female reproductive system Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis GnRH-analogues for ovarian protection in childhood cancer patients: how adult hypotheses are relevant in prepubertal females Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers Triptorelin 3-and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model Dynamic patterns of testosterone levels in individuals and risk of prostate cancer among hypogonadal men: a longitudinal study National Institute for Health and Care Excellence The Controller of Her Majesty's Stationery Office (HMSO) Interrupted time series (ITS) analyses. EPOC Resources for review authors Supply of AstraZeneca medicines Multiple regression: a primer Linear regression models with logarithmic transformations Log-transformation and its implications for data analysis Office for National Statistics. Vital statistics in the UK: births, deaths and marriages-Office for National Statistics ommun ity/popul ation andmi grati on/popul ation estim ates/ datas ets/vital stati stics popul ation andhe althr efere nceta bles 31. Office for National Statistics. Deaths registered monthly in England and Wales-Office for National Statistics birth sdeat hsand marri ages/death s/datas ets/month lyfig ureso ndeat hsreg ister edbya reaof usual resid ence 32. Office for National Statistics. Provisional births in England and Wales Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy Testosterone breakthrough rates during androgen deprivation therapy for castration sensitive prostate cancer Availability of medicines Manufacturing problems cause 60% of medicines shortages, say European wholesalers Interrupted time series regression for the evaluation of public health interventions: a tutorial Gonadorelins adherence in prostate cancer: A time-series analysis of England's national prescriptions during the COVID-19 pandemic